A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 2, 2013, Pages 231-242

  Chen, Jun ^a   Liu, Reng Yun ^b   Yang, Lixin ^c   Zhao, Jun ^a   Zhao, Xueying ^d   Lu, Daru ^d   Yi, Nengjun ^e   Han, Baohui ^f   Chen, Xiao Feng ^g   Zhang, Kui ^e   He, Jun ^a   Lei, Zhe ^b   Zhou, Yifeng ^b   Pasche, Boris ^h   Li, Xiangdong ^a   Zhang, Hong Tao ^b,i  

^a SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f SHANGHAI JIAO TONG UNIVERSITY   (China)

^g SHANGHAI PULMONARY HOSPITAL   (China)

^h University of Alabama at Birmingham   (United States)

ⁱ Suzhou Key Laboratory for Molecular Cancer Genetics   (China)

Author keywords

Haplotype; IL 6; Lung cancer; Risk; Transcriptional activity

Indexed keywords

INTERLEUKIN 6; LUCIFERASE;

ADULT; AGE; ARTICLE; ASSAY; CANCER CELL CULTURE; CANCER RISK; CANCER SUSCEPTIBILITY; CHINESE; CONTROLLED STUDY; FEMALE; GENDER; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; INTERLEUKIN 6 GENE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; AGED; ALLELE; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; MIDDLE AGED; NUCLEOTIDE SEQUENCE; RISK FACTOR; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ADULT; AGED; ALLELES; BASE SEQUENCE; CASE-CONTROL STUDIES; CELL LINE, TUMOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; INTERLEUKIN-6; LINKAGE DISEQUILIBRIUM; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS; TRANSCRIPTIONAL ACTIVATION;

MLCS; MLOWN;

EID: 84874979743     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1314-z     Document Type: Article

References (55)

1. Akey J, Jin L, Xiong M (2001) Haplotypes vs single marker linkage disequilibrium tests: what do we gain? Eur J Hum Genet 9:291-300
2. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539-545
3. Barrett JC, Fry B, Maller J et al (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265
4. Bromberg JF, Wrzeszczynska MH, Devgan G et al (1999) Stat3 as an oncogene. Cell 98:295-303
5. Campa D, Zienolddiny S, Maggini V et al (2004) Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 25:229-235
6. Campa D, Hung RJ, Mates D et al (2005) Lack of association between polymorphisms in inflammatory genes and lung cancer risk. Cancer Epidemiol Biomarkers Prev 14:538-539
7. Colakogullari M, Ulukaya E, Yilmaztepe Oral A et al (2008) The involvement of IL-10, IL-6, IFN-gamma, TNF-alpha and TGF-beta gene polymorphisms among Turkish lung cancer patients. Cell Biochem Funct 26:283-290
8. Cole SW, Arevalo JM, Takahashi R et al (2010) Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci USA 107:5681-5686
9. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860-867
10. Dong LM, Potter JD, White E et al (2008) Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 299:2423-2436
11. Engels EA, Wu X, Gu J et al (2007) Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res 67:6520-6527
12. Fallin D, Schork NJ (2000) Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximization algorithm for unphased diploid genotype data. Am J Hum Genet 67:947-959
13. Fife MS, Ogilvie EM, Kelberman D et al (2005) Novel IL-6 haplotypes and disease association. Genes Immun 6:367-370
14. Fishman D, Faulds G, Jeffery R et al (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369-1376
15. Foster CB, Lehrnbecher T, Samuels S et al (2000) An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood 96:2562-2567
16. Gao SP, Mark KG, Leslie K et al (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117:3846-3856
17. Gazouli M, Zavos G, Papaconstantinou I et al (2004) The interleukin-6-174 promoter polymorphism is associated with a risk of development of Kaposi's sarcoma in renal transplant recipients. Anticancer Res 24:1311-1314
18. Grivennikov S, Karin M (2008) Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 13:7-9
19. Gu W, Du DY, Huang J et al (2008) Identification of interleukin-6 promoter polymorphisms in the Chinese Han population and their functional significance. Crit Care Med 36:1437-1443
20. Hardy J, Singleton A (2009) Genomewide association studies and human disease. N Engl J Med 360:1759-1768
21. Hodge DR, Hurt EM, Farrar WL (2005) The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41:2502-2512
22. Iliopoulos D, Hirsch HA, Struhl K (2009) An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139:693-706
23. Iliopoulos D, Jaeger SA, Hirsch HA et al (2010) STAT3 Activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 39:493-506
24. Johnson GC, Esposito L, Barratt BJ et al (2001) Haplotype tagging for the identification of common disease genes. Nat Genet 29:233-237
25. Joosten PH, Toepoel M, Mariman EC et al (2001) Promoter haplotype combinations of the platelet-derived growth factor alpha-receptor gene predispose to human neural tube defects. Nat Genet 27:215-217
26. Kishimoto T (2005) Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 23:1-21
27. Kitamura A, Hasegawa G, Obayashi H et al (2002) Interleukin-6 polymorphism (-634C/G) in the promotor region and the progression of diabetic nephropathy in type 2 diabetes. Diabet Med 19:1000-1005
28. Knupfer H, Preiss R (2007) Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 102:129-135
29. Landi S, Moreno V, Gioia-Patricola L et al (2003) Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 63:3560-3566
30. Lei Z, Liu RY, Zhao J et al (2009) TGFBR1 haplotypes and risk of non-small-cell lung cancer. Cancer Res 69:7046-7052
31. Lim CS, Zheng S, Kim YS et al (2002) The -174 G to C polymorphism of interleukin-6 gene is very rare in koreans. Cytokine 19:52-54
32. Lin DY, Zeng D (2006) Likelihood-based inference on haplotype effects in genetic association studies. J Am Stat Assoc 101:89-104
33. Liu RY, Song XX, Chen P et al (2012) Association between IL6-174G/C and cancer: a meta-analysis of 105,482 individuals. Exp Ther Med 3:655-664
34. Mander AP (2001) Haplotype analysis in population-based association studies. Stat J 1:58-75
35. Manolio TA, Brooks LD, Collins FS (2008) A HapMap harvest of insights into the genetics of common disease. J Clin Invest 118:1590-1605
36. Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454:436-444
37. Marchenko YV, Carroll RJ, Lin DY et al (2008) Semiparametric analysis of case-control genetic data in the presence of environmental factors. Stat J 8:305-333
38. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215
39. Nakajima T, Ota N, Yoshida H et al (1999) Allelic variants in the interleukin-6 gene and essential hypertension in Japanese women. Genes Immun 1:115-119
40. Okamoto M, Lee C, Oyasu R (1997) Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57:141-146
41. Pan M, Gao SP, Jiang MH et al (2011) Interleukin 6 promoter polymorphisms in normal Han Chinese population: frequencies and effects on inflammatory markers. J Investig Med 59:272-276
42. Park EJ, Lee JH, Yu GY et al (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140:197-208
43. Pisani P, Parkin DM, Munoz N et al (1997) Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 6:387-400
44. Rebouissou S, Amessou M, Couchy G et al (2009) Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457:200-204
45. Seifart C, Plagens A, Dempfle A et al (2005) TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers 21:157-165
46. Seow A, Ng DP, Choo S et al (2006) Joint effect of asthma/atopy and an IL-6 gene polymorphism on lung cancer risk among lifetime non-smoking Chinese women. Carcinogenesis 27:1240-1244
47. Slattery ML, Wolff RK, Herrick J et al (2009) Tumor markers and rectal cancer: support for an inflammation-related pathway. Int J Cancer 125:1698-1704
48. Smith AJ, D'Aiuto F, Palmen J et al (2008) Association of serum interleukin-6 concentration with a functional IL6 -6331T>C polymorphism. Clin Chem 54:841-850
49. Spinka C, Carroll RJ, Chatterjee N (2005) Analysis of case-control studies of genetic and environmental factors with missing genetic information and haplotype-phase ambiguity. Genet Epidemiol 29:108-127
50. Terry CF, Loukaci V, Green FR (2000) Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 275:18138-18144
51. Van Dyke AL, Cote ML, Wenzlaff AS et al (2009) Cytokine and cytokine receptor single-nucleotide polymorphisms predict risk for non-small cell lung cancer among women. Cancer Epidemiol Biomarkers Prev 18:1829-1840
52. Woods KV, Adler-Storthz K, Clayman GL et al (1998) Interleukin-1 regulates interleukin-6 secretion in human oral squamous cell carcinoma in vitro: possible influence of p53 but not human papillomavirus E6/E7. Cancer Res 58:3142-3149
53. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798-809
54. Zhai R, Liu G, Yang C et al (2001) The G to C polymorphism at -174 of the interleukin-6 gene is rare in a Southern Chinese population. Pharmacogenetics 11:699-701
55. Zhong Z, Wen Z, Darnell JE Jr (1994) Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264:95-98